PDA Technical Report 27 remains an indispensable framework for ensuring pharmaceutical package integrity. By moving the industry toward deterministic, data-driven leak detection methods, TR 27 protects both product quality and patient safety. When acquiring the technical report, utilizing official PDA channels ensures your facility relies on authorized, auditable information necessary to build a compliant, world-class contamination control strategy.
: Guidance on establishing microbial barrier effectiveness, which is critical for maintaining sterility. Current Status and Availability Technical Report No. 27: Pharmaceutical Package Integrity pda technical report 27 pdf
is one of the most influential guidance documents in the pharmaceutical and biotechnology industries concerning container closure integrity (CCI). Published by the PDA, a leading global association providing science and technology information for the pharmaceutical and biopharmaceutical communities, this report serves as a foundational reference for evaluating the sterility and stability of packaging systems. PDA Technical Report 27 remains an indispensable framework
TR 27 replaced the older "Aspects of Container/Closure Integrity". Worst-Case Simulation: Published by the PDA, a leading global association
Applying rigorous tracking during manufacturing rather than relying solely on post-production inspection.
: Defining acceptable limits for different package types.
The latest PDA TR 27 (typically referred to as 2021 revision or current version) incorporates updates for advanced therapies (cell/gene therapies, combination products) and new technologies like laser-drilled hole standards.